Valneva Se ADR (VALN)

$10.07 +0.03 (0.30%)
Market Cap 892.93M
Revenue (ttm) 183.50M
Net Income (ttm) -13.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.22%
Debt to Equity Ratio 1.11
Volume 3,100
Avg Vol 22,656
Day's Range N/A - N/A
Shares Out 86.11M
Stochastic %K 79%
Beta 1.83
Analysts Strong Sell
Price Target $12.89

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 2 28 07 37 10
Fax: 33 2 28 07 37 11
Website: valneva.com
Address:
6 rue Alain Bombard, Saint-Herblain, France
Siuolman58
Siuolman58 Jan. 15 at 6:30 PM
$VALN back down to pick up some more
0 · Reply
discountcroesus1
discountcroesus1 Jan. 11 at 3:11 PM
$VALN It smells more and more like a deal with Pfizer... Our friend @Creisi has been saying it for a while now, and it's gone unnoticed. This guy is very well-informed... he proved it with MLTX, which has almost doubled in the last two days, and it's probably not over because, according to him, Merck will buy MLTX within a few weeks. But maybe even more interestingly, it's Biomea that has caught his attention, with a potential 15x increase by autumn 2026, and maybe even 50x by autumn 2027.
0 · Reply
Siuolman58
Siuolman58 Jan. 10 at 11:34 PM
$VALN I smell a deal!!!
0 · Reply
buzzkiller
buzzkiller Jan. 9 at 4:13 PM
$VALN buy out incoming. Hastily announced JPM San Francisco meetings for today. Could be as soon as today.
0 · Reply
Creisi
Creisi Jan. 8 at 4:52 PM
$BMEA $MLTX $VALN Love Biomea Fusion. Icovamenib is a definite blockbuster even better than you think. Amazing drug. $BMEA has now tied $MLTX for the best clinical biopharma investment to make in 2026 and they'll both get a combined total of about 75% of my investment fund. $BMEA will be number 1 as soon as Merck confirms their buy out of $MLTX . My candidate for most likely surprise buyout is VALN. There's simply no way Pfizer is paying VALN a 22% royalty on all Lyme Disease Vaccine sales. Plus, $PFE already own 10% $VALN So $VALN will get at least 15%. I hold a few others that were already purchased, so they're excluded. I'm exploring other candidates to add and will have new choices by January 30, the date I expect MLTX will be part of Merck.
2 · Reply
Creisi
Creisi Jan. 7 at 7:51 PM
$VALN Confirmed. Pfizer's Business Development Department have Valneva on its short list of potential BuyOut candidates. I have no news of any confirmed offer, but this one is perhaps the most obvious in all of Pharma. Pfizer own almost 10% of the company and would need to pony up 22% Royalty Checks annually on all Lyme Vaccine sales. No Big Pharma company pays that kind of royalty check to a small biopharma company they could simply buy and move to the Asset column of their balance sheet. Pfizer will buy these guys before the fall of 2026. Super obvious!
0 · Reply
Creisi
Creisi Jan. 6 at 7:43 PM
$ABVX $VALN I think Pfizer, who already own 9% of VALN will Buy the Out this year instead of giving them a 22% Royalty check annually for the Lyme Disease Vaccine which is nearing BLA submission by the 4th quarter of 2026. I don't have any feelers out on this but damn it makes enough sense that I think I will look into it.
0 · Reply
DaxCo
DaxCo Jan. 6 at 4:03 PM
$ABVX $VALN same same but different. What do you think?
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 4:41 AM
$VALN Current Stock Price: $8.86
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 31 at 5:41 PM
$VALN
0 · Reply
Latest News on VALN
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Jan 9, 2026, 1:00 AM EST - 7 days ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva SE - Declaration of voting rights - December 2025

Jan 8, 2026, 12:30 PM EST - 8 days ago

Valneva SE - Declaration of voting rights - December 2025

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Dec 31, 2025, 11:45 AM EST - 16 days ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Dec 10, 2025, 11:45 AM EST - 5 weeks ago

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

VALNEVA Declaration of shares and voting rights: November 30, 2025

Dec 5, 2025, 12:34 PM EST - 6 weeks ago

VALNEVA Declaration of shares and voting rights: November 30, 2025

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 7 weeks ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

PFE

Valneva to Further Consolidate its Operations in France

Nov 26, 2025, 11:30 AM EST - 7 weeks ago

Valneva to Further Consolidate its Operations in France

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Nov 26, 2025, 6:37 AM EST - 7 weeks ago

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Nov 26, 2025, 1:00 AM EST - 7 weeks ago

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Nov 20, 2025, 3:23 PM EST - 2 months ago

Valneva SE (VALN) Q3 2025 Earnings Call Transcript

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Nov 20, 2025, 1:00 AM EST - 2 months ago

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Nov 4, 2025, 1:00 AM EST - 2 months ago

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Oct 27, 2025, 12:45 PM EDT - 2 months ago

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Oct 6, 2025, 11:35 AM EDT - 3 months ago

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Sep 30, 2025, 1:00 AM EDT - 3 months ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Sep 3, 2025, 1:00 AM EDT - 4 months ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

Aug 25, 2025, 12:02 PM EDT - 5 months ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:43 AM EDT - 5 months ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 10:29 AM EDT - 5 months ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:16 AM EDT - 5 months ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 25, 2025, 1:00 AM EDT - 5 months ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 18, 2025, 1:00 AM EDT - 5 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 3:20 PM EDT - 5 months ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 1:00 AM EDT - 5 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Aug 7, 2025, 1:18 AM EDT - 5 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 29, 2025, 10:00 AM EDT - 6 months ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 11:35 AM EDT - 6 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jul 11, 2025, 8:18 AM EDT - 6 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 26, 2025, 1:00 AM EDT - 7 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 25, 2025, 11:45 AM EDT - 7 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 9, 2025, 10:29 AM EDT - 7 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 5, 2025, 11:45 AM EDT - 8 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Jun 4, 2025, 1:00 AM EDT - 8 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025, 11:30 AM EDT - 8 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 12, 2025, 1:00 AM EDT - 8 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:47 AM EDT - 9 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 8, 2025, 12:30 AM EDT - 9 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 11:45 AM EDT - 9 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 8:40 AM EDT - 9 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 7, 2025, 1:00 AM EDT - 9 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 26, 2025, 1:10 PM EDT - 9 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 18, 2025, 4:00 AM EDT - 9 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 16, 2025, 11:45 AM EDT - 9 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 2:28 PM EDT - 9 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 14, 2025, 11:45 AM EDT - 9 months ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 9, 2025, 1:00 AM EDT - 10 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 9:33 AM EDT - 10 months ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Siuolman58
Siuolman58 Jan. 15 at 6:30 PM
$VALN back down to pick up some more
0 · Reply
discountcroesus1
discountcroesus1 Jan. 11 at 3:11 PM
$VALN It smells more and more like a deal with Pfizer... Our friend @Creisi has been saying it for a while now, and it's gone unnoticed. This guy is very well-informed... he proved it with MLTX, which has almost doubled in the last two days, and it's probably not over because, according to him, Merck will buy MLTX within a few weeks. But maybe even more interestingly, it's Biomea that has caught his attention, with a potential 15x increase by autumn 2026, and maybe even 50x by autumn 2027.
0 · Reply
Siuolman58
Siuolman58 Jan. 10 at 11:34 PM
$VALN I smell a deal!!!
0 · Reply
buzzkiller
buzzkiller Jan. 9 at 4:13 PM
$VALN buy out incoming. Hastily announced JPM San Francisco meetings for today. Could be as soon as today.
0 · Reply
Creisi
Creisi Jan. 8 at 4:52 PM
$BMEA $MLTX $VALN Love Biomea Fusion. Icovamenib is a definite blockbuster even better than you think. Amazing drug. $BMEA has now tied $MLTX for the best clinical biopharma investment to make in 2026 and they'll both get a combined total of about 75% of my investment fund. $BMEA will be number 1 as soon as Merck confirms their buy out of $MLTX . My candidate for most likely surprise buyout is VALN. There's simply no way Pfizer is paying VALN a 22% royalty on all Lyme Disease Vaccine sales. Plus, $PFE already own 10% $VALN So $VALN will get at least 15%. I hold a few others that were already purchased, so they're excluded. I'm exploring other candidates to add and will have new choices by January 30, the date I expect MLTX will be part of Merck.
2 · Reply
Creisi
Creisi Jan. 7 at 7:51 PM
$VALN Confirmed. Pfizer's Business Development Department have Valneva on its short list of potential BuyOut candidates. I have no news of any confirmed offer, but this one is perhaps the most obvious in all of Pharma. Pfizer own almost 10% of the company and would need to pony up 22% Royalty Checks annually on all Lyme Vaccine sales. No Big Pharma company pays that kind of royalty check to a small biopharma company they could simply buy and move to the Asset column of their balance sheet. Pfizer will buy these guys before the fall of 2026. Super obvious!
0 · Reply
Creisi
Creisi Jan. 6 at 7:43 PM
$ABVX $VALN I think Pfizer, who already own 9% of VALN will Buy the Out this year instead of giving them a 22% Royalty check annually for the Lyme Disease Vaccine which is nearing BLA submission by the 4th quarter of 2026. I don't have any feelers out on this but damn it makes enough sense that I think I will look into it.
0 · Reply
DaxCo
DaxCo Jan. 6 at 4:03 PM
$ABVX $VALN same same but different. What do you think?
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 4:41 AM
$VALN Current Stock Price: $8.86
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 31 at 5:41 PM
$VALN
0 · Reply
Siuolman58
Siuolman58 Dec. 30 at 8:56 PM
$VALN Ran the stops!! Collected some nice ones!
0 · Reply
buzzkiller
buzzkiller Dec. 30 at 5:40 PM
$VALN further dilution incoming.
0 · Reply
UnderstatementU
UnderstatementU Dec. 24 at 11:56 AM
$VALN Risk-adjusted upside exists only if resource allocation supports scalability without eroding optionality. Delays or dilution could materially reshape the risk profile.
0 · Reply
TedBaker08
TedBaker08 Dec. 9 at 11:21 AM
$VALN
0 · Reply
Siuolman58
Siuolman58 Dec. 9 at 9:59 AM
$VALN https://www.foxnews.com/us/cdc-warns-americans-traveling-4-countries-outbreak-untreatable-mosquito-disease
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 11:10 PM
$VALN
0 · Reply
Creisi
Creisi Dec. 3 at 3:07 PM
$VALN It's from France and positive news on foreign traded stocks simply don't hit the headlines in the USA like USA based companies do. Had Pfizer released this data, it would have exploded. Valneva need to do their Press Releases in partnership with Pfizer and the response will be 5x better. 45% of the world's investment market is the USA. Focus your PR news releases on the USA market and the impact is magnified. I've been around for over 30 years and have seen this scenario a 1000+ times for non USA companies.
0 · Reply
buzzkiller
buzzkiller Dec. 3 at 2:10 PM
$VALN that the market is continually rejecting any positive sp momentum tells me there is some sort of unspoken issue with this co. -- any guesses?
1 · Reply
BluePeakCapital
BluePeakCapital Dec. 2 at 2:41 PM
$VALN
0 · Reply
ajmore
ajmore Dec. 2 at 10:15 AM
$VALN pfizer's set back on the covid front due to myocarditis will leave them with no option but to acquire valneva for the covid vaccine. just a reminder, novavax vlp vaccine had issues with myocarditis too!
0 · Reply
buzzkiller
buzzkiller Dec. 1 at 11:07 AM
$VALN high school kids in Atlanta beating this company..
0 · Reply
Creisi
Creisi Nov. 30 at 7:37 PM
$VALN This vaccine is also effective against the Lone Star Tick which turns eating meat into a death sentence... this tick is also becoming prominent in the Southwest and as far up the coast as Maine... 2 weeks ago a NYC resident died after being bitten by a Lone Star Tick and then eating a hamburger. The market opportunity for a Lyme Disease Vaccine is a game changer and USA sales projections are grossly underestimated by analysts. Anyone that does anything outside is going to get this vaccine... it makes no sense not to. Virtually zero side effects and extremely protective. With Pfizer making a BLA submission in 2026 to market the Vaccine on VALNEVA's behalf, this little vaccine company will be bought by Pfizer by October 2026 or will report huge earnings by 2027 thrusting this stock price will into the $50-60 range either way.
1 · Reply